Genome & Company

Seongnam-si, South Korea Founded: 2015 • Age: 11 yrs
Microbiome-based immuno-oncology drugs are developed using proprietary technology.
Request Access

About Genome & Company

Genome & Company is a company based in Seongnam-si (South Korea) founded in 2015 by Jisoo Pae.. The company has 102 employees as of December 31, 2024. Genome & Company has completed 1 acquisition, including List Biological Laboratories. Genome & Company operates in a competitive market with competitors including Moderna, BeiGene, Incyte, Novozymes and Ultragenyx, among others.

  • Headquarter Seongnam-si, South Korea
  • Employees 102 as on 31 Dec, 2024
  • Founders Jisoo Pae
  • Stage Public
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Legal Name Genome & Co.
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research
Healthcare → Healthcare Products & Supplies
Healthcare → Pharmaceuticals & Therapeutics
Healthcare → Biotechnology, Genomics & Life Sciences Research
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
    $18.81 M (USD)
    94.07
    as on Dec 31, 2024
  • Net Profit
    $-13.64 M (USD)
    57.63
    as on Dec 31, 2024
  • EBITDA
    $-12.02 M (USD)
    63.04
    as on Dec 31, 2024
  • Latest Funding Round
    $2.96 M (USD), Post-IPO

    Apr 28, 2020

  • Investors
  • Employee Count
    102

    as on Dec 31, 2024

  • Investments & Acquisitions
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

IPO & Listings of Genome & Company

Genome & Company is a publicly listed company on the KRX with ticker symbol 314130 in South Korea, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

Exchange: KRX · Ticker: 314130 . Sector: Health technology · South Korea

Funding Insights of Genome & Company

  • Total Funding
  • Total Rounds 2
  • Last Round Post-IPO — $3.0M
  • First Round
  • Investors Count 2
Date Amount Transaction Name Valuation Lead Investors Investors
Apr, 2020 Amount Post-IPO - Genome & Company Valuation

investors

Jun, 2016 Amount Seed - Genome & Company Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Genome & Company

Genome & Company has secured backing from 2 investors, including institutional and venture fund investors. Prominent investors backing the company include DongKoo Bio& Pharma and DSC Investment. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Early-stage venture capital is invested primarily in South Korean startups.
Founded Year Domain Location
Company focused on generic medicines, OTC, stem cell extraction kits, medical apparatus, cosmetics & CMO services
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Genome & Company

Genome & Company has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include List Biological Laboratories. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Acquisitions
Company Name Description Domain Location Founded Year Amount
Specializes in the production of research reagents
1978
Company Name Description Domain Location Founded Year Amount
OVO is recognized as a smart digital payment application.
2017
Bionic investment advisor platform
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014

Financial Statements - Genome Company

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Genome & Company Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Genome & Company

Genome & Company operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BeiGene, Incyte, Novozymes and Ultragenyx, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
mRNA-based therapeutics for diseases including cancer and infections are developed.
domain founded_year HQ Location
Targeted and immune-oncology drugs for cancer treatment are developed.
domain founded_year HQ Location
Small molecules are developed for cancer and skin disease treatments.
domain founded_year HQ Location
Biosolutions and enzymes are developed for biotechnology applications across industries.
domain founded_year HQ Location
Therapeutics for rare and ultra-rare metabolic diseases are developed.
domain founded_year HQ Location
Therapeutics for cancer and rare diseases are developed.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Genome & Company

Frequently Asked Questions about Genome & Company

When was Genome & Company founded?

Genome & Company was founded in 2015 and raised its 1st funding round 1 year after it was founded.

Where is Genome & Company located?

Genome & Company is headquartered in Seongnam-si, South Korea. It is registered at Seongnam-si, Gyeonggi-do, South Korea.

Who is the current CEO of Genome & Company?

Jisoo Pae is the current CEO of Genome & Company. They have also founded this company.

How many employees does Genome & Company have?

As of Dec 31, 2024, the latest employee count at Genome & Company is 102.

What is the annual revenue of Genome & Company?

Annual revenue of Genome & Company is $18.81M as on Dec 31, 2024.

What does Genome & Company do?

The company was founded in 2015 in Seongnam-si, South Korea, and operates in the biotechnology sector focused on microbiome therapeutics. Innovative drug candidates are developed through the GNOCLE platform, targeting immuno-oncology and other conditions. The pipeline includes GEN-001 and GEN-004 for cancer treatments, as well as SB-121 for autism and obstetric diseases. Leadership is provided by Co-Founder and CEO Jisoo Pae.

Who are the top competitors of Genome & Company?

Genome & Company's top competitors include Moderna, BeiGene and Novozymes.

Is Genome & Company publicly traded?

Yes, Genome & Company is publicly traded on KRX under the ticker symbol 314130.

How many acquisitions has Genome & Company made?

Genome & Company has made 1 acquisition, including List Biological Laboratories.

Who are Genome & Company's investors?

Genome & Company has 2 investors. Key investors include DongKoo Bio& Pharma, and DSC Investment.

What is Genome & Company's ticker symbol?

The ticker symbol of Genome & Company is 314130 on KRX.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available